The primary purpose of this study is to evaluate the tolerability and safety profile of ASP8374 in participants with locally advanced (unresectable) or metastatic solid tumors. Also primary purpose is to characterize the pharmacokinetic profile of ASP8374 and to determine the recommended Phase 2 dose (RP2D) of ASP8374.